How Aspirin Inhibits Clotting to Prevent Strokes
Aspirin blocks the enzyme cyclooxygenase-1 (COX-1) in platelets, reducing production of thromboxane A2, a chemical that triggers platelet aggregation and promotes blood clots.[1] This antiplatelet effect lasts for the platelet's lifespan (7-10 days), thinning blood and lowering clot risk without broadly affecting coagulation.
Which Strokes Does It Target?
Aspirin primarily protects against ischemic strokes, which account for 87% of cases and occur when clots block brain arteries, starving tissue of oxygen.[2] It has no benefit—and may increase risk—for hemorrhagic strokes from vessel rupture, as thinner blood worsens bleeding.[1][2]
How It Lowers Stroke Risk in Practice
By curbing platelet clumping, aspirin prevents clots from forming on ruptured plaques in carotid or cerebral arteries. Trials like the Physicians' Health Study showed 44 mg daily aspirin cut ischemic stroke risk by 20% in healthy men, while higher doses (75-325 mg) reduce recurrence after a first stroke by 22%.[3][4] Benefits peak in those with atrial fibrillation or prior events, where clots often embolize to the brain.
What Dosage and Timing Work Best?
Low-dose aspirin (81-325 mg daily) balances efficacy and safety; enteric-coated versions reduce stomach irritation.[1] Start post-event or for high-risk patients (e.g., age >55 with cardiovascular factors); daily use inhibits 95% of thromboxane within hours, with cumulative effects over weeks.[5] Guidelines recommend it for secondary prevention but not routine primary use due to bleeding trade-offs.[2]
Common Risks and Who Should Avoid It
Bleeding is the main downside: aspirin doubles gastrointestinal bleed risk (2-4% annually) and slightly raises hemorrhagic stroke odds (0.1-0.2% yearly).[3] Avoid in ulcer history, recent surgery, or with anticoagulants like warfarin. Black patients see less benefit for primary prevention.[2]
How It Compares to Other Anti-Clotting Drugs
| Drug | Mechanism | Stroke Risk Reduction | Bleeding Risk |
|------|-----------|-----------------------|---------------|
| Aspirin | Inhibits platelet aggregation | 20-25% (ischemic) [3] | Moderate |
| Clopidogrel (Plavix) | Blocks ADP receptor on platelets | Similar to aspirin; better post-stent [6] | Comparable |
| Ticagrelor (Brilinta) | Reversible P2Y12 inhibitor | 16% better than clopidogrel in ACS [7] | Higher |
| Warfarin/DOACs | Inhibit clotting factors | 60-70% in atrial fibrillation [2] | High (needs monitoring for warfarin) |
Aspirin is cheapest and over-the-counter, but dual therapy (aspirin + clopidogrel) boosts protection short-term after stroke.[6]
[1]: https://www.ncbi.nlm.nih.gov/books/NBK519032/
[2]: https://www.aha.org/
[3]: Antithrombotic Trialists' Collaboration, BMJ 2009
[4]: Physicians' Health Study, NEJM 1989
[5]: Patrono C, NEJM 2004
[6]: CAPRIE trial, Lancet 1996
[7]: PLATO trial, NEJM 2009